Can a tuberculosis vaccine help fight HIV? new study explores
NCT ID NCT05004038
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether the BCG vaccine, normally used to prevent tuberculosis, could reduce the hidden HIV reservoir in people living with HIV who are on antiretroviral therapy. Sixty participants received either a single BCG shot or a placebo. Researchers measured changes in HIV DNA levels in blood cells over six months to see if the vaccine could help control the virus.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BCG vaccine (Bacillus Calmette-Guérin)
What this could lead to
If successful, this could show that BCG vaccination helps shrink the hidden HIV reservoir, potentially pointing toward a way to better control or even eliminate HIV.
What could go wrong
This is a small, early-phase study with only 60 participants. The effect on the HIV reservoir may be minimal or temporary, and BCG is not a cure for HIV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital Zurich
Zurich, 8091, Switzerland